Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

Jingye Gong, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2024-212110

Published: 2024

Journal Articles

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Fuhui Li, Yudi Zhang, Chengwen Li, Qi Sun, Jinqin Liu, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6734.

https://doi.org/10.1182/blood-2024-200761

Published: 2024

Journal Articles

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

Xin Wang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Bing Li, Li Juan Pan, Qingyan Gao, Meng Jiao, Jinying Zhao, Wenjun Xie, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6729.

https://doi.org/10.1182/blood-2024-199104

Published: 2024

Journal Articles

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

Zefeng Xu, Ling Pan, Zhenya Hong, Qingsong Yin, Xuelan Zuo, Qin Wen, Fan Yu, Chunkang Chang, Wei Ling, Dong Wang, Dawei Ding, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2023-178956

Published: 2023

Journal Articles

U2AF1 S34F Mutation Promote Megakaryopoiesis and Fibrogenesis in MDS

Wenjun Zhang, Jinqin Liu, Lin Yang, Yiru Yan, Tiejun Qin, Zefeng Xu, Gang Huang, Bing Li, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 5685.

https://doi.org/10.1182/blood-2023-185678

Published: 2023

Journal Articles

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Li Juan Pan, Robert Peter Gale, Bing Li, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2023-184604

Published: 2023

Journal Articles

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Junying Wu, Wenjun Zhang, Peihong Zhang, Tiejun Qin, Zefeng Xu, Qi Sun, Yujiao Jia, Shiqiang Qu, Bing Li, Huijun Wang, Lijuan Pan, Jinqin Liu, Yudi Zhang, Xin Yan, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 4058–4059.

https://doi.org/10.1182/blood-2022-163019

Published: 2022

Journal Articles

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

Yudi Zhang, Junying Wu, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Huijun Wang, Xin Yan, Jingye Gong, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 1343–1345.

https://doi.org/10.1182/blood-2022-160131

Published: 2022

Journal Articles

IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Qingyan Gao, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 4092–4093.

https://doi.org/10.1182/blood-2022-165083

Published: 2022

Journal Articles

Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis

Xin Yan, Zefeng Xu, Shiqiang Qu, Tiejun Qin, Gang Huang, Zhijian Xiao, Bing Li

Blood (2022) 140 (Supplement 1): 3965–3967.

https://doi.org/10.1182/blood-2022-165185

Published: 2022

Journal Articles

Clonal Architecture Analysis of TET2 Identified Distinct Origins in Myelodysplastic Syndromes

Zhongxun Shi, MD, Bing Li, MD, Tiejun Qin, MD, Zefeng Xu, MD, Lijuan Pan, MD, Shiqiang Qu, MD, Gang Huang, PhD, Zhijian Xiao, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-139329

Published: 2020

Journal Articles

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Bing Li, MD, Jinqin Liu, Tiejun Qin, Zefeng Xu, MD, Gang Huang, PhD, Zhijian Xiao, MD

Blood (2019) 134 (Supplement_1): 2979.

https://doi.org/10.1182/blood-2019-126346

Published: 2019

Journal Articles

Clinical Features and Biological Implications of U2AF1 Mutations in Myelodysplastic Syndromes

Bing Li, Jinqin Liu, Yujiao Jia, MD, Tiejun Qin, Zefeng Xu, MD, Yue Zhang, MD PhD, Gang Huang, PhD, Zhijian Xiao

Blood (2017) 130 (Supplement 1): 586.

https://doi.org/10.1182/blood.V130.Suppl_1.586.586

Published: 2017

Journal Articles

HIF1A Is a Critical Downstream Mediator for Hemophagocytic Lymphohistiocytosis

Blood (2017) 130 (Supplement 1): 3565.

https://doi.org/10.1182/blood.V130.Suppl_1.3565.3565

Published: 2017

Journal Articles

Non-Driver Mutations Profile Identified By a 206-Gene NGS Panel in Patients with Primary Myelofibrosis and Post-Polycythaemic/Essential Thromocythaemia Myelofibrosis in a Single Center from China

Bing Li, MD, Lei Zhang, MD, Jie Bai, MD PhD, Zefeng Xu, MD, Tiejun Qin, Yue Zhang, MD, Jinqin Liu, Gang Huang, PhD, Zhijian Xiao, MD

Blood (2016) 128 (22): 1942.

https://doi.org/10.1182/blood.V128.22.1942.1942

Published: 2016

Journal Articles

EPO Signaling Triggers Erythrocytosis By Expanding Erythrocytes and Also Subsets of Macrophages

Yoshihiro Hayashi, MD PhD, Jieyu Wang, MD, Zefeng Xu, MD, Xiaomei Yan, MD PhD, Yue Zhang, MD, Theodosia A Kalfa, MD PhD, Zhijian Xiao, MD, Gang Huang, PhD

Blood (2016) 128 (22): 542.

https://doi.org/10.1182/blood.V128.22.542.542

Published: 2016

Journal Articles

Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Sonja Zweegman, MD PhD, Peter Te Boekhorst, Suzan Commandeur, MSc, Harry C. Schouten, Federico Sackmann, MD, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, Karen Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean Christophe Ianotto, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD PhD, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Tiziano Barbui, MD, Giovanni Barosi, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Bjorn Andreasson, Maria Ferrari, Alessandro Rambaldi, MD, Jan Samuelsson, MD PhD, Keith Cannon, MD, Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa, MD

Blood (2016) 128 (22): 5463.

https://doi.org/10.1182/blood.V128.22.5463.5463

Published: 2016

Journal Articles

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

Robyn M. Scherber, MD MPH, Holly Geyer, MD, Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Sonja Zweegman, MD PhD, Peter Te Boekhorst, Suzan Commandeur, MSc, Harry C. Schouten, Federico Sackmann, MD, Ana Kerguelen Fuentes, MD, Dolores Hernandez-Maraver, PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Konstanze Doehner, MD, Thomas Lehmann, Karen Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean Christophe Ianotto, Dana Ranta, MD, Lydia Roy, MD, Jean-Yves Cahn, MD, Claire N. Harrison, DM, FRCP, FRCPath, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Pablo J. Muxi, MD, Norman I Maldonado, MD, Carlos Besses, MD PhD, Francisco Cervantes, MD PhD, Peter L. Johansson, MD PhD, Tiziano Barbui, MD, Giovanni Barosi, Alessandro M. Vannucchi, MD, Bjorn Andreasson, Maria Ferarri, Alessandro Rambaldi, MD, Jan Samuelsson, MD PhD, Gunnar Birgegard, MD PhD, Keith Cannon, MD, Xuijuan Sun, Junqing Xu, Peihong Zhang, Zefeng Xu, Ruben A. Mesa, MD

Blood (2016) 128 (22): 3117.

https://doi.org/10.1182/blood.V128.22.3117.3117

Published: 2016

Journal Articles

Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy

Holly Geyer, MD, Robyn M. Scherber, MD MPH, Heidi Kosiorek, M.S., Amylou C. Dueck, PhD, Jean-Jacques Kiladjian, MD PhD, Stefanie Slot, Zhijian Xiao, DO, Sonja Zweegman, MD PhD, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernandez-Maraver, PhD, Konstanze Döhner, MD, Claire N. Harrison, Deepti Radia, Pablo J. Muxi, MD, Carlos Besses, Francisco Cervantes, Peter L. Johansson, MD PhD, Bjorn Andreasson, MDPhD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Karin Bonatz, Andreas Reiter, MD, Francoise Boyer, MD, Gabriel Etienne, MD PhD, Jean-Christophe Ianotto, MD, Dana Ranta, Lydia Roy, MD, Jean-Yves Cahn, Norman I Maldonado, MD, Giovanni Barosi, MD, Maria Ferrari, Robert Peter Gale, MD PhD DSc, Gunnar Birgegard, MD PhD, Zefeng Xu, MD, Yu Zhang, B.S., Xiujuan Sun, MD, Junqing Xu, Peihong Zhang, Peter A. te Boekhorst, Suzan Commandeur, Harry C. Schouten, MD PhD, Heike L Pahl, PhD, Martin Griesshammer, MD, Frank Stegelmann, MD, Thomas Lehmann, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Jan Samuelsson, MD PhD, Ruben A. Mesa, MD

Blood (2015) 126 (23): 5175.

https://doi.org/10.1182/blood.V126.23.5175.5175

Published: 2015

Journal Articles

Activation of HIF-2a-EPO Axis in Kidney or Liver Is Sufficient to Drive Erythrocytosis in a Novel Inducible HIF-2a Transgenic Mouse Model

Jieyu Wang, MD, Yoshihiro Hayashi, MD PhD, Zefeng Xu, MD, Lingyun Wu, MD PhD, Xiaomei Yan, MD PhD, Theodosia A. Kalfa, MD PhD, Zhijian Xiao, MD, Gang Huang, PhD

Blood (2015) 126 (23): 931.

https://doi.org/10.1182/blood.V126.23.931.931

Published: 2015

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Factors Associated with Progression to Overt Acute Myeloid Leukemia in NPM1 -Mutated Myeloid Neoplasms with Less Than 10% Blasts

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

U2AF1 S34F Mutation Promote Megakaryopoiesis and Fibrogenesis in MDS

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old

Mutational Landscape, Clonal Evolution and Prognostic Effect of Non-Driver Mutations during Disease Progression of Primary Myelofibrosis

Clonal Architecture Analysis of TET2 Identified Distinct Origins in Myelodysplastic Syndromes

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Clinical Features and Biological Implications of U2AF1 Mutations in Myelodysplastic Syndromes

HIF1A Is a Critical Downstream Mediator for Hemophagocytic Lymphohistiocytosis

Non-Driver Mutations Profile Identified By a 206-Gene NGS Panel in Patients with Primary Myelofibrosis and Post-Polycythaemic/Essential Thromocythaemia Myelofibrosis in a Single Center from China

EPO Signaling Triggers Erythrocytosis By Expanding Erythrocytes and Also Subsets of Macrophages

Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy

Activation of HIF-2a-EPO Axis in Kidney or Liver Is Sufficient to Drive Erythrocytosis in a Novel Inducible HIF-2a Transgenic Mouse Model

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only